

## Discovery of an orally available pre-clinical candidate for age-related macular degeneration

JD Bioscience Inc.



OPHTHALMOLOGY	Candidate
Product Type	Small molecule
Indication	Age-related macular degeneration (AMD)
Target	PDK4 inhibitor
MoA(Mechanism of Action)	PDK4 inhibitor suppresses PDHE1 phosphorylation and activates PDC. Improving the mitochondrial function of retinal cells that are metabolically reprogrammed by inflammatory and hypoxic environment, alleviates neovascularization by reducing overexpressed HIF-1 $\alpha$ and VEGF.
Competitiveness	<ol style="list-style-type: none"> <li>1. Currently, there are no available oral medications for neovascular age related macular degeneration. Furthermore, there are no PDK4 inhibitors developed for indications for ophthalmic diseases.</li> <li>2. An oral preparation will relieve patients' fear and the incidence of complication. Additionally, less frequent visits by oral medication will reduce the medical cost and financial burden.</li> </ol>
Development Stage	Candidate
Route of Administration	Oral medication

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*